Sign up

Perceptive Advisors LLC

$6.4B assets · 102 holdings · Q2 2026 · Filed 14 AUG 2026

About Perceptive Advisors LLC’s 13F portfolio

Perceptive Advisors LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Perceptive Advisors LLC reported $6.4B across 102 US-listed positions (). Its largest position is PRAXIS PRECISION MEDICINES I (PRAX) at 11% of the reported book, and its ten biggest holdings make up 49% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$6.4B
Assets (13F)
#681
of 8,839 by size
102
Holdings
49%
Top-10 weight
53
Buys
39
Sells
Top holdings · Q2 2026
102 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: PRAX
PRAXIS PRECISION MEDICINES I
$305.19
+0.04%
11%
2.0M$681.6M
2
NASDAQ: SYRE
SPYRE THERAPEUTICS INC
$101.46
+8.15%
6.0%
4.3M$383.5M
3
NASDAQ: CELC
CELCUITY INC
$55.60
−4.15%
5.2%
3.2M$334.5M
4
NASDAQ: ASND
ASCENDIS PHARMA A/S
$270.33
−0.32%
4.8%
1.2M$310.4M
5
NASDAQ: RYTM
RHYTHM PHARMACEUTICALS INC
$119.04
+2.08%
4.5%
2.6M$287.2M
6
NASDAQ: ROIV
ROIVANT SCIENCES LTD
$38.73
+0.05%
4.4%
8.1M$286.1M
7
NASDAQ: RLAY
RELAY THERAPEUTICS INC
$16.51
+0.24%
4.1%
14.1M$263.9M
8
NASDAQ: TVTX
TRAVERE THERAPEUTICS INC
$50.24
−1.68%
3.3%
3.8M$213.2M
9
NASDAQ: KARD
KARDIGAN INC
—
—
3.0%
8.2M$195.6M
10
NASDAQ: NUVL
NUVALENT INC
$123.96
0.00%
3.0%
1.6M$195.2M
11
NASDAQ: EWTX
EDGEWISE THERAPEUTICS INC
$41.37
−1.59%
2.8%
4.4M$177.7M
12
NASDAQ: APGE
APOGEE THERAPEUTICS INC
$135.07
0.00%
2.7%
1.3M$173.6M
13
NASDAQ: AMLX
AMYLYX PHARMACEUTICALS INC
$26.62
−3.27%
2.3%
8.3M$149.7M
14
NASDAQ: MGTX
MEIRAGTX HLDGS PLC
$8.32
−1.65%
2.3%
10.8M$145.7M
15
NASDAQ: ORKA
ORUKA THERAPEUTICS INC
$95.74
−0.60%
2.0%
1.3M$128.0M
16
NASDAQ: INBX
INHIBRX BIOSCIENCES INC
$69.06
−6.90%
1.9%
1.3M$123.0M
17
NASDAQ: PTGX
PROTAGONIST THERAPEUTICS INC
$127.16
+2.00%
1.9%
982K$120.4M
18
NASDAQ: SLDB
SOLID BIOSCIENCES INC
$6.35
+1.93%
1.8%
11.9M$118.9M
19
NASDAQ: ZYME
ZYMEWORKS INC
$26.04
+0.77%
1.7%
4.2M$109.3M
20
NASDAQ: TNGX
TANGO THERAPEUTICS INC
$21.89
−1.00%
1.6%
3.4M$105.6M
21
NASDAQ: IMTX
IMMATICS N.V
$6.10
−3.02%
1.6%
10.4M$105.2M
22
NASDAQ: NRIX
NURIX THERAPEUTICS INC
$14.10
−0.98%
1.6%
4.3M$104.8M
23
NASDAQ: BCRX
BIOCRYST PHARMACEUTICALS INC
$7.30
−2.67%
1.6%
10.3M$103.1M
24
NASDAQ: RVMD
REVOLUTION MEDICINES INC
$159.82
−1.76%
1.5%
528K$98.8M
25
NASDAQ: AVLN
AVALYN PHARMACEUTICALS INC
—
—
1.4%
2.7M$88.1M

Showing 1–25 of 102 positions on this page reported in this 13F.

Sector allocation
  • Healthcare94%
Recent activity · vs 2026-03-31
Bought53
  • AddedSYRESPYRE THERAPEUTICS INC+14.2%$383.5M
  • AddedCELCCELCUITY INC+2.2%$334.5M
  • NewASNDASCENDIS PHARMA A/S—$310.4M
  • AddedRYTMRHYTHM PHARMACEUTICALS INC+9.0%$287.2M
  • AddedRLAYRELAY THERAPEUTICS INC+44.7%$263.9M
  • NewKARDKARDIGAN INC—$195.6M
  • AddedAMLXAMYLYX PHARMACEUTICALS INC+0.6%$149.7M
  • AddedMGTXMEIRAGTX HLDGS PLC+4.5%$145.7M
  • AddedZYMEZYMEWORKS INC+19.2%$109.3M
  • AddedTNGXTANGO THERAPEUTICS INC+318%$105.6M
Sold39
  • ReducedROIVROIVANT SCIENCES LTD−2.4%$286.1M
  • ReducedTVTXTRAVERE THERAPEUTICS INC−9.4%$213.2M
  • ReducedEWTXEDGEWISE THERAPEUTICS INC−1.1%$177.7M
  • ReducedAPGEAPOGEE THERAPEUTICS INC−15.1%$173.6M
  • ReducedORKAORUKA THERAPEUTICS INC−3.6%$128.0M
  • ReducedINBXINHIBRX BIOSCIENCES INC−10.0%$123.0M
  • ReducedPTGXPROTAGONIST THERAPEUTICS INC−20.2%$120.4M
  • ReducedDYNDYNE THERAPEUTICS INC−42.4%$59.7M
  • ReducedIMVTIMMUNOVANT INC−15.0%$52.3M
  • ReducedANROALTO NEUROSCIENCE INC−19.9%$42.5M
5%+ Beneficial Ownership Stakes · 8 activist (13D) · 31 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
ADGM
Adagio Medical Holdings, Inc.
13G57.5% · 3 classes15.3MFiled 17 FEB 2026
2
LONA
LeonaBio, Inc.
13D20.0% · 2 classes1.9MFiled 26 OCT 2026
3
SLDB
Solid Biosciences Inc.
13D12.9% · 2 classes12.0MFiled 11 MAR 2026
4
MGTX
MeiraGTx Holdings plc
13D12.9% · 2 classes10.4MFiled 02 JAN 2026
5
FRNM
Freenome, Inc.
13G11.3%12.6MFiled 16 NOV 2026
6
NAUT
Nautilus Biotechnology, Inc.
13D10.1%12.8MFiled 24 JUN 2025
7
TRIB
Trinity Biotech plc
13D10.0% · 3 classes54.1MFiled 10 NOV 2026
8
PALI
PALISADE BIO, INC.
13G10.0% · 2 classes15.2MFiled 17 FEB 2026
9
IKT
INHIBIKASE THERAPEUTICS, INC.
13G10.0% · 2 classes12.8MFiled 17 FEB 2026
10
IRD
Opus Genetics, Inc.
13G10.0% · 2 classes7.2MFiled 17 FEB 2026
11
ENGN
enGene Holdings Inc.
13G10.0% · 3 classes6.9MFiled 14 AUG 2026
12
OBIO
Orchestra BioMed Holdings, Inc.
13G10.0% · 2 classes5.7MFiled 14 NOV 2025
13
ANRO
Alto Neuroscience, Inc.
13G10.0% · 2 classes4.2MFiled 14 AUG 2026
14
NVNO
enVVeno Medical Corporation
13G10.0%2.0MFiled 17 FEB 2026
15
VYNE
Yarrow Bioscience, Inc.
13G10.0%1.6MFiled 16 NOV 2026
16
INBX
INHIBRX BIOSCIENCES, INC.
13G10.0%1.5MFiled 14 AUG 2026
17
KPHMW
KIORA PHARMACEUTICALS, INC.
13G10.0%442KFiled 10 AUG 2026
18
RLAY
KIORA PHARMACEUTICALS, INC.
13G10.0% · 2 classes438KFiled 13 APR 2026
19
TENX
Tenax Therapeutics, Inc.
13G9.1%569KFiled 17 FEB 2026
20
RACD
Research Alliance Corporation IV
13G9.0%700KFiled 16 NOV 2026
21
KARD
Kardigan, Inc.
13D8.8%8.3MFiled 01 OCT 2026
22
QNCX
IRulya Therapeutics Inc.
13G8.4%913KFiled 14 OCT 2026
23
AMLX
Amylyx Pharmaceuticals, Inc.
13G8.2% · 2 classes9.0MFiled 14 NOV 2025
24
XFOR
X4 PHARMACEUTICALS, INC.
13G8.1% · 2 classes8.1MFiled 14 AUG 2026
25
IVVD
INVIVYD, INC.
13G7.9%21.8MFiled 25 NOV 2025

Showing 1–25 of 39 disclosed stakes. 5 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Perceptive Advisors LLC’s 13F portfolio

Perceptive Advisors LLC’s $6.4B 13F book is spread across 102 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 49%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are PRAX, SYRE, CELC, ASND and RYTM, led by PRAXIS PRECISION MEDICINES I (PRAX) at 11% of the portfolio. The heaviest sector exposure is Healthcare (94%).

What Perceptive Advisors LLC changed last quarter

Between 2026-03-31 and Q2 2026, Perceptive Advisors LLC was a net buyer: it opened 23 new positions and added to 30 more, while trimming 26 and closing 13 outright. Against a 102-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was SPYRE THERAPEUTICS INC (SYRE), and its biggest reduction was ROIVANT SCIENCES LTD (ROIV).

What a 13F does and doesn’t reveal

A 13F captures only Perceptive Advisors LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Perceptive Advisors LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Perceptive Advisors LLC's profile on this page is built directly from those filings.

How current is the 13F data on Perceptive Advisors LLC's page?

It reflects Perceptive Advisors LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Perceptive Advisors LLC files its next quarterly report, this page refreshes automatically.

Can I see Perceptive Advisors LLC's complete list of holdings?

This page highlights Perceptive Advisors LLC's largest positions rather than all 102 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Perceptive Advisors LLC's filings.

Does a 13F show everything Perceptive Advisors LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Perceptive Advisors LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Perceptive Advisors LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.